A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 920-928

  Petropoulos, Christos J ^a,b   Parkin, Neil T ^a   Limoli, Kay L ^a   Lie, Yolanda S ^a   Wrin, Terri ^a   Huang, Wei ^a   Tian, Huan ^a   Smith, Douglas ^a   Winslow, Genine A ^a   Capon, Daniel J ^a,c   Whitcomb, Jeannette M ^a  

^a MONOGRAM BIOSCIENCES   (United States)

^b Genetic Information Systems Inc ^*  (United States)

^c Genetic Information Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS VECTOR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; GENETIC VECTORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0034019566     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.920-928.2000     Document Type: Article

References (68)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Ausubel, F. (ed.). 1999. Current protocols in molecular biology, vol. 1 and 2. John Wiley & Sons, Inc., New York, N.Y.
3. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, M. Duran, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
4. Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
5. Byrnes, V. W., E. A. Emini, W. A. Schleif, J. H. Condra, C. L. Schneider, W. J. Long, J. A. Wolfgang, D. J. Graham, L. Gotlib, A. J. Schlabach, B. S. Wolanski, O. M. Blahy, J. C. Quintero, A. Rhodes, E. Rothy, D. L. Titus, and V. V. Sardana. 1994. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 38:1404-1407.
6. Capon, D. Nov. 1998. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. U.S. patent 5,837,464.
7. Carpenter, C. C. J., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA 283:381-390.
8. Casado, J., M. Perez-Elias, A. Antela, R. Sabido, P. Marti-Belda, F. Dronda, J. Blazquez, and C. Quereda. 1998. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 12: F131-F135.
9. Condra, J., W. Schleif, O. Blahy, L. Gabryelski, D. Graham, J. Quintero, A. Rhodes, H. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yan, H. Teppler, K. Squires, P. Deutsch, and E. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
10. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
11. Decks, S. G., and D. I. Abrams. 1997. Genotypic-resistance assays and antiretroviral therapy. Lancet 349:1489-1490.
12. Decks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179:1375-1381.
13. de Jong, J., J. Goudsmit, V. Lukashov, M. Hillebrand, E. Baan, R. Huismans, S. Danner, J. ten Veen, F. de Wolf, and S. Jurriaans. 1999. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 13:75-80.
14. Durant, J., P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C. A. Boucher, J. M. Schapiro, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
15. Eastman, P. S., E. Boyer, L. Mole, J. Kolberg, M. Urdea, and M. Holodniy. 1995. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J. Clin. Microbiol. 33:2777-2780.
16. Egger, M., B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Rickenbach, R. Malinverni, P. Vernazza, and M. Battegay. 1997. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br. Med. J. 315:1194-1199.
17. Erickson, J., S. Gulnik, and M. Markowitz. 1999. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13(Suppl. A):S189-S204.
18. Fatkenheuer, G., A. Theisen, J. Rockstroh, T. Grabow, C. Wicke, K. Becker, U. Wieland, H. Pfister, M. Reiser, P. Hegener, C. Franzen, A. Schwenk, and B. Salzberger. 1997. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11(14):F113-F116.
19. Fiscus, S. A., M. D. Hughes, J. L. Lathey, T. Pi, B. Jackson, S. Rasheed, T. Elbeik, R. Reichman, A. Japour, R. Byinglon, W. Scott, B. P. Griffith, D. A. Katzenstein, and S. M. Hammer. 1998. Changes in virologie markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. J. Infect. Dis. 177:625-633.
20. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-didoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
21. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
22. Goudsmit, J., A. De Ronde, D. Ho, and A. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5664.
23. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
24. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group Study Team. N. Engl. J. Med. 337:725-733.
25. Harrigan, P., K. Hertogs, W. Verbiest, R. Pauwels, B. Larder, S. Kemp, S. Bloor, B. Yip, R. Hogg, C. Alexander, and J. Montaner. 1999. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhihitor therapy in a community setting. AIDS 13(14):1863-1871.
26. Hartley, J. W., and W. P. Rowe. 1976. Naturally occuring murine leukemia viruses in wild mice: characterization of a new amphotropic class. J. Virol. 19:19-25.
27. Havlir, D., J. Whitcomb, N. Hellmann, C. Petropoulos, A. Collier, M. Hirsch, P. Tebas, and D. Richman. 2000. Drug susceptibility in HIV isolates obtained after viral rebound from patients receiving an indinavir containing regimen. JAMA 283:229-234.
28. Hecht, F. M., R. M. Grant, C. J. Petropoulos, B. Dillon, M. A. Chesney, H. Tian, N. S. Hellmann, N. I. Bandrapalli, L. Digilio, B. Branson, and J. O. Kahn. 1998. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339:307-311.
29. Hertogs, K., M.-P. De Béthune, V. Miller, T. Ivens, P. Schel, A. V. Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
30. Hirsch, M., R. Steigbigel, S. Staszewski, J. Mellors, E. Scerpella, B. Hirschel, J. Lange, S. K., S. Rawlins, A. Meiboh, and R. Leavitt. 1999. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J. Infect. Dis. 180:659-665.
31. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezient, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:1984-1991.
32. Hirschel, B., and M. Opravil. 1999. The year in review: antiretroviral treatment. AIDS 13(Suppl. A):S177-S187.
33. Hogg, R., B. Yip, C. Kully, K. Craib, M. O'Shaunghnessy, M. Schechter, and J. Montaner. 1999. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can. Med. Assoc. J. 160: 659-665.
34. Iversen, A., R. Shafer, K. Wehrly, M. Winters, J. Mullins, B. Cheseboro, and T. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
35. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, The RV-43 Study Group and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
36. Kellam, P., C. Boucher, J. Tijnagel, and B. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
37. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
38. Keulen, W., N. K. Back, A. van Wijk, C. A. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
39. Landau, N. R., K. A. Page, and D. R. Littman. 1991. Pseudotyping with human T-cell leukemia virus type 1 broadens the human immunodeficiency virus host range. J. Virol. 65:162-169.
40. Lanier, R., S. Danehower, S. Daluge, A. Cutrell, M. Tisdale, G. Pearce, B. Spreen, S. Lafon, S. Kemp, S. Bloor, and B. Larder. 1998. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). Antivir. Ther. 3(Suppl. 1):36.
41. Larder, B., S. Bloor, S. Kemp, K. Hertogs, R. Desmet, V. Miller, M. Sturmer, S. Staszewski, J. Ren, D. Stammers, D. Stuart, and R. Pauwels. 1999. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1961-1967.
42. Larder, B., P. Kellam, and S. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365:451-453.
43. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
44. Little, S., E. Daar, R. D'Aquila, P. Keiser, E. Connick, J. Whitcomb, N. Hellmann, C. Petropoulos, J. Pitt, E. Rosenberg, R. Koup, and D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
45. Lorenzi, P., M. Opravil, B. Hirschel, J. P. Chave, H. J. Furrer, H. Sax, T. V. Perneger, L. Perrin, L. Kaiser, and S. Yerly. 1999. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 13(2):F17-F21.
46. Marschner, I. C., A. C. Collier, R. W. Coombs, R. T. D'Aquila, V. DeGruttola, M. A. Fischl, S. M. Hammer, M. D. Hughes, V. A. Johnson, D. A. Katzenstein, D. D. Richman, L. M. Smeaton, S. A. Spector, and M. S. Saag. 1998. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177:40-47.
47. Meijer, A., A. van Loon, J. C. Borleffs, and G. Roozendaal. 1995. Development of molecular methods for detection and epidemiological investigation of HIV-1, HIV-2, and HTLV I/II infections 118504001. National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
48. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946-954.
49. Mouton, Y., S. Alfandari, M. Valette, F. Cartier, P. Dellamonica, G. Humbert, J. Lang, P. Massip, D. Michali, P. Leclercq, J. Modal, and H. Portier. 1997. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 11(12):F101-F105.
50. Myers, G., S. Wain-Hobson, B. Korber, R. F. Smith, and G. N. Pavlakis. 1996. Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N.M.
51. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
52. Parkin, N., Y. Lie, N. Hellmann, M. Markowitz, S. Bonhoeffer, D. Ho, and C. Petropoulos. 1999. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J. Infect. Dis. 180:865-870.
53. Patick, A., M. Zhang, K. Hertogs, L. Griffiths, E. Mazabel, R. Pauwels, and M. Becker. 1998. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Antivir. Ther. 3(Suppl. 1):39.
54. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
55. Piketty, C., E. Race, P. Castiel, L. Belec, G. Peytavin, A. si-Mohamed, G. Gonzalez-Canali, L. Weiss, F. Clavel, and M. Kazatchkine. 1999. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 13(11):F71-F77.
56. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. BioTechniques 8:404-407.
57. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1999. Mutations in retroviral genes associated with drug resistance. Intl. Antivir. News 7:46-69.
58. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
59. Schuurman, R., D. Brambilla, T. deGroot, and C. Boucher. 1999. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel. Antivir. Ther. 4(Suppl. 1):41.
60. Schuurman, R., L. Demeter, P. Reichelderfer, J. Tijnagel, T. de Groot, and C. Boucher. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37:2291-2296.
61. Shargel, L., and A. B. C. Yu. 1993. Applied biopharmaceutics and pharmacokinetics, 3rd ed. Appleton & Lange, Norwalk, Conn.
62. Shirasaka, T., M. Kavlick, T. Ueno, W. Gao, E. Kojima, M. Alcaide, S. Chokekijchai, B. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
63. Stuyver, L., A. Wyseur, A. Rombout, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. Schinazi, and R. Rossau. 1997. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:284-291.
64. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
65. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Vlair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
66. Whitcomb, J., K. Limoli, T. Wrin, D. Smith, H. Tian, N. Parkin, Y. Lie, and C. Petropoulos. 1998. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Antivir. Ther. 3(Suppl. 1):14.
67. Winters, M., K. Coolley, Y. Girard, D. Levee, H. Hamdan, R. Shafer, D. Katzenstein, and T. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers to multiple nucleoside inhibitors. J. Clin. Invest. 102:1769-1775.
68. Zolopa, A., R. Shafer, A. Warford, J. Montoya, P. Ilsu, D. Katzenstein, T. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.